Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

15.80
-0.0600-0.38%
Post-market: 15.800.00000.00%17:04 EDT
Volume:1.91M
Turnover:30.09M
Market Cap:2.70B
PE:-5.79
High:16.04
Open:16.04
Low:15.44
Close:15.86
Loading ...

Immunovant Cut to Neutral From Buy by UBS

Dow Jones
·
22 Apr

UBS Downgrades Immunovant to Neutral, Price Target is $17

MT Newswires Live
·
22 Apr

Immunovant downgraded to Neutral from Buy at UBS

TIPRANKS
·
22 Apr

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Caution Deepens Amid Intensifying Tariff Escalations

MT Newswires Live
·
21 Apr

Immunovant Names New CEO, CFO

MT Newswires Live
·
21 Apr

BRIEF-Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications

Reuters
·
21 Apr

Immunovant CEO Salzmann Retires; Roivant Exec Venker Takes the Helm

Dow Jones
·
21 Apr

Immunovant Inc - Tiago Girao Appointed as CFO of Immunovant

THOMSON REUTERS
·
21 Apr

Immunovant Inc - Ind Cleared for Imvt-1402 in Sjd, Study to Initiate Summer 2025

THOMSON REUTERS
·
21 Apr

Immunovant Inc - Current Cash Balance Provides Runway Through Graves’ Disease Readout in 2027

THOMSON REUTERS
·
21 Apr

Immunovant Announces Next Phase of Growth With Roivant Including Changes to Its Leadership Team and Additional Indications SjÖGren’s Disease (Sjd) and Cutaneous Lupus Erythematosus (Cle) for Imvt-1402

THOMSON REUTERS
·
21 Apr

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

GlobeNewswire
·
21 Apr

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

Insider Monkey
·
08 Apr

Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?

Insider Monkey
·
26 Mar

BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate

Reuters
·
21 Mar

Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space

TIPRANKS
·
21 Mar

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Zacks
·
20 Mar

Immunovant Is Maintained at Buy by B of A Securities

Dow Jones
·
20 Mar

Immunovant price target lowered to $33 from $38 at BofA

TIPRANKS
·
20 Mar

Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar